Lividomycin is a broad-spectrum aminoglycoside antibiotic. It is effective against most Gram-positive and Gram-negative bacteria including Mycobacterium tuberculosis (the causative agent of tuberculosis) and Pseudomonas aeruginosa.
{{Drugbox | IUPAC_name = (1R,2R,3S,4R,6S)-4,6-Diamino-3-hydroxy-2-{[α-D-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-β-L-idopyranosyl-(1->3)-β-D-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-α-D-ribo-hexopyranoside | image = Lividomycin A.svg | image_class = skin-invert-image | CAS_number = 36441-41-5 | CAS_number_Ref = | UNII_Ref = | UNII = A606AJ494W | ATC_prefix = | ATC_suffix = | PubChem = 72394 | DrugBank = DB04728 | ChEBI_Ref = | ChEBI = 71961 | ChEMBL = 389029 | ChemSpiderID = 65327 | C=29 | H=55 | N=5 |O=19 | smiles = O([C@H]4[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@H]2O[C@@H](CN)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[C@H](O)[C@H]2N)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]4N)[C@H]5O[C@@H]([C@@H](O)C[C@H]5N)CO | StdInChI = 1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1 | StdInChIKey = DBLVDAUGBTYDFR-SWMBIRFSSA-N | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}
Lividomycin is a broad-spectrum aminoglycoside antibiotic. It is effective against most Gram-positive and Gram-negative bacteria including Mycobacterium tuberculosis (the causative agent of tuberculosis) and Pseudomonas aeruginosa.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).